Codiak BioSciences Shares Outstanding 2020-2021 | CDAK

Codiak BioSciences shares outstanding from 2020 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Codiak BioSciences Annual Shares Outstanding
(Millions of Shares)
2020 6
2019 3
Codiak BioSciences Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 22
2021-03-31 20
2020-12-31 6
2020-09-30 3
2020-06-30 3
2020-03-31 3
2019-12-31
2019-09-30 3
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.382B $0.003B
Codiak BioSciences Inc. is a clinical-stage biopharmaceutical company. It is focused on development of exosome-based therapeutics for spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. Codiak BioSciences Inc. is based in CAMBRIDGE, Mass.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $132.971B 8.85
Bio-Rad Laboratories (BIO.B) United States $22.624B 48.22
QIAGEN (QGEN) Netherlands $12.001B 20.32
Biohaven Pharmaceutical Holding (BHVN) United States $8.691B 0.00
Emergent Biosolutions (EBS) United States $2.870B 6.92
Arcus Biosciences (RCUS) United States $2.690B 0.00
Myovant Sciences (MYOV) United Kingdom $2.182B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.045B 0.00
Zymeworks (ZYME) Canada $1.373B 0.00
Ambrx Biopharma (AMAM) United States $0.501B 0.00
SQZ Biotechnologies (SQZ) United States $0.442B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29